CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical.
It is a $10.3B healthcare company. Revenue grew 4.7% over the last year, it keeps 13¢ of every dollar of sales as profit, and its net debt equals ~3.5 years of free cash flow. It trades at 18.1× earnings — in the cheapest third of its own history.
- Website
- coopercos.com
- Location
- San Ramon, CA
- Employees
- 15 000
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong valuation and quality; Growth, Profitability and Health lag behind.
Valuation77
- P/E vs own history12th pct · 25/25
- FCF yield6.6% · 20/25
- P/S2.4x · 20/25
- EV/EBITDA17.3x · 12/25
Growth49
- Revenue CAGR8.8% · 12/25
- Net income CAGR-40.3% · 0/25
- EPS CAGR ~5Y9.3% · 12/25
- Fwd implied growth53.3% · 25/25
Profitability42
- ROIC3.5% · 5/25
- ROE6.9% · 5/25
- Net margin13.5% · 20/25
- Operating margin12.8% · 12/25
Health42
- Altman Zn/a · 0/25
- Current ratio1.22 · 12/25
- Interest coverage6.2x · 18/25
- Net cash / debtD/A 19% · 12/25
Quality90
- Piotroski F6/9 · 15/25
- Beneish M-2.55 · 25/25
- FCF conversion119% · 25/25
- Margin stabilityσ 2.7% · 25/25
Moat68
- ROIC >12% years0/10 yrs · 0/25
- Median gross margin65.1% · 25/25
- FCF-positive years10/10 yrs · 25/25
- Worst-year net marginworst 5.5% · 18/25
Experience
The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.
- Q3 2026Insiders5 open-market insider purchases~35K shares bought by insiders
- 2022AcquisitionCooperSurgical acquired Cook Medical's reproductive health business for $875 million
- FY2021FinancialBest year on record$2.94B net income
- 2021AcquisitionA month later, in March, the company acquired Safe Obstetric Systems
- FY2016FinancialProfitable every year on record10 consecutive profitable years in our data
- FY2016FinancialRevenue already above $1B$1.97B in first reported year
- FY2016FinancialPositive free cash flow every year since10-year streak
- 2005AcquisitionOcular Sciences Inc. was acquired by CooperVision in 2005
- 2003MilestoneThree years later, it was further restructured into three business units: CooperVision, CooperSurgical and…
- 1990MilestoneIt became a business unit in 1990 and its focus includes women's health and fertility
- 1987MilestoneThe company was renamed The Cooper Companies in 1987
- 1980MilestoneCooper Laboratories reorganized into three business groups: CooperVision, CooperCare and CooperBiomedical
- 1967AcquisitionIts name was changed to Cooper Laboratories Inc. in 1967, and entered the contact lens business when it acquired…
- 1961MilestoneThe company was renamed to Cooper, Tinsley Laboratories, Inc. in 1961
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- High gross margin (65.9%)
- Strong cash conversion — FCF is 16.0% of revenue
- Interest covered 6.2× by operating earnings
Watch-outs
Nothing stands out as a concern in the available data.
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year ago+4.7% YoY
- Profitable — makes more than it spends$570M TTM
- Profit growing — earnings are higher than last year-1.1% YoY
- Generates cash — cash left after running and investing$678M TTM
- Debt under control — could handle its obligations~3.5y of cash flow to repay
- Established company — not a micro-cap — lower blow-up risk$10.3B market cap
- Not printing shares — share count not ballooning — you keep your slice+0.8% shares over ~5y
- Proven track record — years of profitability behind it10/10 profitable years
- Financially stable — balance sheet not near distresshealth score 30/100
- Pays a dividend — returns cash to shareholdersnone
- Valuation not extreme — price not wildly above earningsP/E 18.1
Peer comparisonThe Cooper Companies, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| COO this company | $10.3B | 18.1 | +4.7% | 13.5% | Strained |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: COO vs LLY · COO vs JNJ · COO vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2016–FY2025. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/COO
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of COO on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $54.37 · market cap $10.3B.